Corbalan R, et al. - In this cohort study of a registry with 52,014 patients, researchers evaluated treatment strategies and 1-year clinical outcomes of antithrombotic and congestive heart failure (CHF) therapies for newly diagnosed atrial fibrillation patients with etiologically stratified concomitant CHF (ischemic cardiomyopathy [ICM] vs nonischemic cardiomyopathy [NICM]). Investigators found that ICM patients received oral anticoagulants less frequently with or without antiplatelet drugs and more frequently received antiplatelets alone vs NICM patients; they also received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers more frequently than NICM patients. The rate of all-cause and cardiovascular death in ICM patients was higher than in NICM patients.